logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals CEO details new global pneumonia trial for Traumakine

Faron Pharmaceuticals Oy's (LON:FARN) chief executive Dr Markku Jalkanen tells Proactive London's Andrew Scott its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia.

The study also includes patients suffering from the latest virus outbreak.

The interferon beta-1 formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients.

Quick facts: Faron Pharmaceuticals Ltd

Price: 331.9 GBX

AIM:FARN
Market: AIM
Market Cap: £155.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO details new US Traumakine study and updates on Clevegen...

Faron Pharmaceuticals' (LON:FARN) Dr Markku Jalkanen speaks to Proactive London's Andrew Scott following a successful virtual R&D day this week. He also reports on the continued progress for two of its clinical stage programmes, Clevegen and Traumakine, including the just-announced...

4 weeks ago

2 min read